Pfizer-biontech announce positive topline results of pivotal covid-19 vaccine study in adolescents

New york and mainz, germany, march 31, 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that, in a phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of sars-cov-2 infection, the pfizer-biontech covid-19 vaccine bnt162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. these are topline results from a pivotal phase 3 trial in 2,260 adolescents.
BNTX Ratings Summary
BNTX Quant Ranking